Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:AVXL NASDAQ:HRTX NASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.14+0.3%$3.55$1.24▼$4.08$832.54M1.024.27 million shs2.51 million shsAVXLAnavex Life Sciences$9.64+4.6%$10.53$4.93▼$14.44$827.98M0.83883,327 shs881,720 shsHRTXHeron Therapeutics$1.35-2.9%$1.79$1.04▼$2.68$206.94M1.232.58 million shs1.14 million shsPHATPhathom Pharmaceuticals$12.18-1.5%$9.58$2.21▼$19.71$864.10M0.441.13 million shs600,362 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-1.57%-15.59%-3.38%+102.58%AVXLAnavex Life Sciences0.00%+1.15%-13.93%+27.51%+60.13%HRTXHeron Therapeutics0.00%-3.57%-20.12%-30.05%-30.05%PHATPhathom Pharmaceuticals0.00%+2.27%+45.87%+162.50%-26.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics3.7638 of 5 stars3.52.00.04.02.20.80.6AVXLAnavex Life Sciences3.8169 of 5 stars3.51.00.04.72.90.80.6HRTXHeron Therapeutics3.9888 of 5 stars3.21.00.04.22.83.30.6PHATPhathom Pharmaceuticals2.5755 of 5 stars3.51.00.00.01.84.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.00Buy$6.75114.97% UpsideAVXLAnavex Life Sciences 3.00Buy$44.00356.43% UpsideHRTXHeron Therapeutics 2.33Hold$4.50233.33% UpsidePHATPhathom Pharmaceuticals 3.00Buy$17.5043.68% UpsideCurrent Analyst Ratings BreakdownLatest HRTX, PHAT, AVXL, and AKBA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.008/22/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.008/13/2025AKBAAkebia TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.008/12/2025HRTXHeron TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell8/8/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.008/4/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.006/9/2025HRTXHeron TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.006/9/2025PHATPhathom PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $17.006/9/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/6/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M5.20N/AN/A($0.23) per share-13.65AVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/AHRTXHeron Therapeutics$144.29M1.43N/AN/A($0.22) per share-6.14PHATPhathom Pharmaceuticals$114.04M7.58N/AN/A($3.71) per share-3.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)AVXLAnavex Life Sciences-$43M-$0.57N/AN/AN/AN/A-45.67%-40.21%N/AHRTXHeron Therapeutics-$13.58M-$0.02N/AN/AN/A-0.62%N/A-0.40%11/11/2025 (Estimated)PHATPhathom Pharmaceuticals-$334.33M-$4.73N/AN/AN/A-289.51%N/A-90.40%11/6/2025 (Estimated)Latest HRTX, PHAT, AVXL, and AKBA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q3 2025AVXLAnavex Life Sciences-$0.13-$0.16-$0.03-$0.16N/AN/A8/8/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 million$37.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AAVXLAnavex Life SciencesN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.611.981.84AVXLAnavex Life SciencesN/A8.938.93HRTXHeron TherapeuticsN/A0.820.53PHATPhathom PharmaceuticalsN/A2.382.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%AVXLAnavex Life Sciences31.55%HRTXHeron Therapeutics80.01%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%AVXLAnavex Life Sciences11.00%HRTXHeron Therapeutics5.86%PHATPhathom Pharmaceuticals23.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430265.14 million257.19 millionOptionableAVXLAnavex Life Sciences4085.89 million76.45 millionOptionableHRTXHeron Therapeutics300153.29 million144.31 millionOptionablePHATPhathom Pharmaceuticals11070.94 million53.85 millionOptionableHRTX, PHAT, AVXL, and AKBA HeadlinesRecent News About These CompaniesPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 25, 2025 | globenewswire.comWall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a BetAugust 22, 2025 | zacks.comPhathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D FilingAugust 20, 2025 | taiwannews.com.twTPhathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D FilingAugust 20, 2025 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 4.4% - Still a Buy?August 16, 2025 | marketbeat.comPhathom Pharmaceuticals (PHAT) Gets a Buy from H.C. WainwrightAugust 14, 2025 | theglobeandmail.comPhathom Pharmaceuticals (PHAT) Gets a Buy from GuggenheimAugust 14, 2025 | theglobeandmail.comPhathom Pharmaceuticals’ Earnings Call Highlights Growth and ChallengesAugust 13, 2025 | msn.comPhathom Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS In LineAugust 9, 2025 | finance.yahoo.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | insidermonkey.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading 11.7% Higher - Here's What HappenedAugust 8, 2025 | marketbeat.comPhathom (PHAT) Q2 Revenue Jumps 441%August 8, 2025 | theglobeandmail.comPhathom projects $165M–$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growthAugust 8, 2025 | msn.comPhathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comPhathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue EstimatesAugust 7, 2025 | zacks.comPhathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 7, 2025 | globenewswire.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Rating of "Buy" by BrokeragesAugust 7, 2025 | marketbeat.comXTX Topco Ltd Invests $565,000 in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)August 7, 2025 | marketbeat.comCraig-Hallum Keeps Their Buy Rating on Phathom Pharmaceuticals (PHAT)August 6, 2025 | theglobeandmail.comPhathom Pharmaceuticals (PHAT) to Release Earnings on ThursdayAugust 1, 2025 | marketbeat.comPhathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025July 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRTX, PHAT, AVXL, and AKBA Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.14 +0.01 (+0.32%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.12 -0.02 (-0.48%) As of 08/29/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Anavex Life Sciences NASDAQ:AVXL$9.64 +0.42 (+4.56%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$9.68 +0.04 (+0.41%) As of 08/29/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Heron Therapeutics NASDAQ:HRTX$1.35 -0.04 (-2.88%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.38 +0.02 (+1.85%) As of 08/29/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Phathom Pharmaceuticals NASDAQ:PHAT$12.18 -0.18 (-1.46%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$12.24 +0.06 (+0.53%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
